Genix Pharmaceuticals Corporation (TSXV:GENX)

Genix Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 30, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Revenue	0	0	0.01	-	-	-
Revenue Growth (YoY)	-81.17%	-67.19%	-	-	-	-
Cost of Revenue	0.18	0.18	0.01	-	0	-
Gross Profit	-0.18	-0.18	0	-	-0	-
Selling, General & Admin	0.14	0.15	0.23	0.18	0.26	0.22
Operating Expenses	0.16	0.18	0.84	1	1.61	0.68
Operating Income	-0.35	-0.36	-0.83	-1	-1.61	-0.68
Interest Expense	-0.15	-0.12	-0.05	-0.01	-0	-0
Interest & Investment Income	0	0	0	0	0	0
Currency Exchange Gain (Loss)	-0	-0	-0.01	-0.03	0	-0
Other Non Operating Income (Expenses)	-0.06	-0.06	-0.05	-0.03	-0.05	-0.04
EBT Excluding Unusual Items	-0.56	-0.55	-0.94	-1.07	-1.65	-0.72
Asset Writedown	-	-	-3.46	-	-	-
Other Unusual Items	0.47	0.47	-	-	-	-
Pretax Income	-0.09	-0.07	-4.4	-1.07	-1.65	-0.72
Earnings From Continuing Operations	-0.09	-0.07	-4.4	-1.07	-1.65	-0.72
Net Income	-0.09	-0.07	-4.4	-1.07	-1.65	-0.72
Net Income to Common	-0.09	-0.07	-4.4	-1.07	-1.65	-0.72
Shares Outstanding (Basic)	59	59	59	59	59	50
Shares Outstanding (Diluted)	59	59	59	59	59	50
Shares Change (YoY)	-	-	-	-	18.55%	33.17%
EPS (Basic)	-0.00	-0.00	-0.07	-0.02	-0.03	-0.01
EPS (Diluted)	-0.00	-0.00	-0.07	-0.02	-0.03	-0.01
Free Cash Flow	-0.16	-0.19	-0.22	-0.22	-0.43	-0.2
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	-0.01	-0.00
Gross Margin	-	-	26.43%	-	-	-
Operating Margin	-32548.92%	-8986.67%	-6737.05%	-	-	-
Profit Margin	-8193.91%	-1806.86%	-35600.34%	-	-	-
Free Cash Flow Margin	-15334.68%	-4624.54%	-1787.27%	-	-	-
EBITDA	0.2	0.18	-0.29	-0.46	-1.09	-0.32
EBITDA Margin	18649.58%	4498.59%	-	-	-	-
D&A For EBITDA	0.55	0.55	0.55	0.54	0.52	0.36
EBIT	-0.35	-0.36	-0.83	-1	-1.61	-0.68
Revenue as Reported	0	0	0.01	-	-	-

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.